 BILLERICA, Mass.--BUSINESS WIRE--Quanterix Corporation NASDAQ: QTRX, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Simoa technology has been used in a worldwide collaborative study of the plasma neurofilament light NfL biomarker to evaluate its utility for a range of neurological conditions. Published in Nature Communications, the research marks the most robust effort to date assessing the use of NfL in blood 